{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:07:08Z","timestamp":1790089628126,"version":"4.0.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with multiple myeloma are frequently exposed to prolonged, multiline and multidrug treatments, factors that may substantially influence overall health, physical reserve, and physiological resilience. Imaging of organs that are captured by whole-body scans can be opportunistically interrogated to derive direct, quantitative measures of body composition. Advances and standardization of whole-body magnetic resonance imaging (WBMRI) together with recent improvements in artificial intelligence (AI) methodologies for automated organ and tissue segmentation presents an opportunity to complement accurate disease assessments with body composition metrics. We report, to our knowledge, for the first time, development of an AI-based pipeline to enable automated quantitative image-derived phenotypes in nondiseased tissue from WBMRI in patients with multiple myeloma. We have demonstrated that a deep-learning pipeline can derive body composition metrics from routinely acquired clinical WBMRI. Throughout treatment, significant longitudinal changes were observed (P&amp;lt; .001), characterized by a decrease in abdominal skeletal muscle (ASM) alongside transient increases in abdominal subcutaneous and visceral adipose tissue. We have also shown that greater reserves of ASM (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.40-0.89) and abdominal subcutaneous adipose tissue (HR, 0.67; 95% CI, 0.46-0.98) at baseline are associated with better progression-free survival. Conversely increases in visceral adipose tissue over time was associated with inferior progression-free survival (HR, 2.89; 95% CI, 1.65-5.09). These findings support opportunistic body composition phenotyping from diagnostic WBMRI as a scalable biomarker for risk stratification (concordance index, 0.725) and mechanistic study. This trial was registered at www.clinicaltrials.gov as NCT02403102.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020852","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:18:12Z","timestamp":1783531092000},"page":"6103-6111","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["AI-derived whole-body MRI metrics in patients with multiple myeloma reveal unique insights into body composition and outcomes"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-0913","authenticated-orcid":false,"given":"Nicolas","family":"Basty","sequence":"first","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3677-4804","authenticated-orcid":false,"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"},{"name":"2The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-0028","authenticated-orcid":false,"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"},{"name":"2The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5362-6934","authenticated-orcid":false,"given":"Kevin","family":"Boyd","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Smith","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-4466","authenticated-orcid":false,"given":"Karen","family":"Thomas","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-2167","authenticated-orcid":false,"given":"Nuria","family":"Porta","sequence":"additional","affiliation":[{"name":"2The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Meo","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6564-5016","authenticated-orcid":false,"given":"Robby","family":"Emsley","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-5252","authenticated-orcid":false,"given":"Jessica","family":"Winfield","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"},{"name":"2The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8344-195X","authenticated-orcid":false,"given":"Alina","family":"Dragan","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8569-9188","authenticated-orcid":false,"given":"Simon","family":"Doran","sequence":"additional","affiliation":[{"name":"2The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dow-Mu","family":"Koh","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"},{"name":"2The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-2399","authenticated-orcid":false,"given":"Brandon","family":"Whitcher","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-9379","authenticated-orcid":false,"given":"Christina","family":"Messiou","sequence":"additional","affiliation":[{"name":"1The Royal Marsden NHS Foundation Trust, London, United Kingdom"},{"name":"2The Institute of Cancer Research, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"6","key":"2026092210524471000_bib1","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026092210524471000_bib2","volume-title":"Myeloma: Diagnosis and Management","year":"2016"},{"issue":"4","key":"2026092210524471000_bib3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/bjh.19716","article-title":"Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: a British Society of Haematology and UK Myeloma Society Good Practice Paper","volume":"205","author":"Kaiser","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"2026092210524471000_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-025-01327-4","article-title":"Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma","volume":"15","author":"Messiou","year":"2025","journal-title":"Blood Cancer J"},{"issue":"17","key":"2026092210524471000_bib5","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1002\/cam4.4136","article-title":"Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry","volume":"10","author":"Belotti","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"2026092210524471000_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"issue":"1","key":"2026092210524471000_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","article-title":"METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer","volume":"71","author":"Padhani","year":"2017","journal-title":"Eur Urol"},{"key":"2026092210524471000_bib8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1148\/radiol.2021201740","article-title":"Oncologically relevant findings reporting and data system (ONCO-RADS): guidelines for the acquisition, interpretation, and reporting of whole-body MRI for cancer screening","volume":"299","author":"Petralia","year":"2021","journal-title":"Radiology"},{"issue":"9","key":"2026092210524471000_bib9","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma\u2014a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2026092210524471000_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ageing\/afz046","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"issue":"3","key":"2026092210524471000_bib11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cncr.34545","article-title":"Sarcopenia identified by computed tomography imaging using a deep learning\u2013based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma","volume":"129","author":"Nandakumar","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"2026092210524471000_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s13244-015-0414-0","article-title":"Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome","volume":"6","author":"Yip","year":"2015","journal-title":"Insights Imaging"},{"issue":"1","key":"2026092210524471000_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41408-022-00782-7","article-title":"Extreme body mass index and survival in newly diagnosed multiple myeloma patients","volume":"13","author":"Shah","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026092210524471000_bib14","doi-asserted-by":"crossref","first-page":"e65554","DOI":"10.7554\/eLife.65554","article-title":"Genetic architecture of 11 organ traits derived from abdominal MRI using deep learning","volume":"10","author":"Liu","year":"2021","journal-title":"elife"},{"issue":"4","key":"2026092210524471000_bib15","doi-asserted-by":"crossref","first-page":"e0283506","DOI":"10.1371\/journal.pone.0283506","article-title":"Abdominal imaging associates body composition with COVID-19 severity","volume":"18","author":"Basty","year":"2023 13","journal-title":"PLoS one"},{"key":"2026092210524471000_bib16","doi-asserted-by":"crossref","first-page":"1288657","DOI":"10.3389\/fphys.2024.1288657","article-title":"Precision MRI phenotyping of muscle volume and quality at a population scale","volume":"15","author":"Thanaj","year":"2024","journal-title":"Front Physiol"},{"issue":"1","key":"2026092210524471000_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13244-022-01253-0","article-title":"Implementation of whole-body MRI (MY-RADS) within the OPTIMUM\/MUKnine multi-centre clinical trial for patients with myeloma","volume":"13","author":"Rata","year":"2022","journal-title":"Insights Imaging"},{"key":"2026092210524471000_bib18","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2007.01251","article-title":"Image processing and quality control for abdominal magnetic resonance imaging in the UK Biobank","author":"Basty","year":"16  2020","journal-title":"arXiv"},{"issue":"1","key":"2026092210524471000_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12894-015-0087-5","article-title":"Five-point Likert scaling on MRI predicts clinically significant prostate carcinoma","volume":"15","author":"Harada","year":"2015","journal-title":"BMC Urol"},{"issue":"5","key":"2026092210524471000_bib20","doi-asserted-by":"crossref","first-page":"e210048","DOI":"10.1148\/rycan.2021210048","article-title":"Prospective evaluation of whole-body MRI versus FDG PET\/CT for lesion detection in participants with myeloma","volume":"3","author":"Messiou","year":"2021","journal-title":"Radiol Imaging Cancer"},{"issue":"8","key":"2026092210524471000_bib21","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"2026092210524471000_bib22","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"12","key":"2026092210524471000_bib23","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026092210524471000_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1214\/aos\/1176344136","article-title":"Estimating the dimension of a model","volume":"6","author":"Schwarz","year":"1978","journal-title":"Ann Statist"},{"issue":"18","key":"2026092210524471000_bib25","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"Jama"},{"issue":"suppl 1","key":"2026092210524471000_bib26","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2018-99-116920","article-title":"Geriatric impairments and low muscle mass are associated with treatment discontinuation and overall survival in newly diagnosed non-transplant eligible multiple myeloma patients (nte-NDMM) treated with dose-adjusted melphalan-prednisone-bortezomib (MPV)\u2014results of the Dutch HOVON 123 study","volume":"132","author":"Stege","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2026092210524471000_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41408-023-00934-3","article-title":"Muscle and fat composition in patients with newly diagnosed multiple myeloma","volume":"13","author":"Abdallah","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026092210524471000_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41409-020-01008-9","article-title":"Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation","volume":"56","author":"Williams","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"2026092210524471000_bib29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.clml.2016.04.010","article-title":"Prognostic effect of low subcutaneous adipose tissue on survival outcome in patients with multiple myeloma","volume":"16","author":"Takeoka","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"2026092210524471000_bib30","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1182\/blood.V122.21.5326.5326","article-title":"Psoas cross-sectional area as radiographic measure of sarcopenia does not predict overall survival in multiple myeloma","volume":"122","author":"Bhamidipati","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2026092210524471000_bib31","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.hpb.2025.03.450","article-title":"\u201cObesity Paradox\u201d as a new insight from long-term survivors in pancreatic cancer patients","volume":"27","author":"Lee","year":"2025","journal-title":"HPB (Oxford)"},{"issue":"1","key":"2026092210524471000_bib32","doi-asserted-by":"crossref","first-page":"26455","DOI":"10.1038\/s41598-025-11560-3","article-title":"AI-based body composition analysis of CT data has the potential to predict disease course in patients with multiple myeloma","volume":"15","author":"Wegner","year":"2025","journal-title":"Sci Rep"},{"issue":"6","key":"2026092210524471000_bib33","first-page":"535","article-title":"Body composition phenotypes and obesity paradox","volume":"18","author":"Prado","year":"2015","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"40","key":"2026092210524471000_bib34","doi-asserted-by":"crossref","first-page":"68460","DOI":"10.18632\/oncotarget.19536","article-title":"Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma\u2013subgroup analysis of the prospective GMMG MM5 trial","volume":"8","author":"Gro\u00df","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2026092210524471000_bib35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12957-025-04007-6","article-title":"Sarcopenia and fat loss from serial CT predict survival in multiple myeloma patients undergoing stem cell transplantation","volume":"23","author":"Kylies","year":"2025","journal-title":"World J Surg Oncol"},{"issue":"19","key":"2026092210524471000_bib36","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3390\/diagnostics15192466","article-title":"AI-based 3D-segmentation quantifies sarcopenia in multiple myeloma patients","volume":"15","author":"Do","year":"2025","journal-title":"Diagnostics"},{"issue":"1","key":"2026092210524471000_bib37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1186\/s13063-022-06848-y","article-title":"Telehealth exercise to improve physical function and frailty in patients with multiple myeloma treated with autologous hematopoietic Stem cell transplantation (TIPS): protocol of a randomized controlled trial","volume":"23","author":"Lee","year":"2022","journal-title":"Trials"},{"issue":"1","key":"2026092210524471000_bib38","doi-asserted-by":"crossref","first-page":"e64905","DOI":"10.2196\/64905","article-title":"Prehabilitation exercise training to target improved muscle strength in pretransplant patients diagnosed with multiple myeloma: protocol for a pilot randomized controlled trial","volume":"13","author":"Normann","year":"2024","journal-title":"JMIR Res Protoc"},{"issue":"1","key":"2026092210524471000_bib39","doi-asserted-by":"crossref","first-page":"e002936","DOI":"10.1136\/bmjoq-2024-002936","article-title":"Real-world evaluation of physiotherapist-led exercise prehabilitation and rehabilitation during autologous stem cell transplantation in myeloma: a single-centre experience","volume":"14","author":"Land","year":"2025","journal-title":"BMJ Open Qual"},{"issue":"13","key":"2026092210524471000_bib40","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6103\/2587730\/blooda_adv-2026-020852-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6103\/2587730\/blooda_adv-2026-020852-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:51Z","timestamp":1790088771000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6103\/569591\/AI-derived-whole-body-MRI-metrics-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":40,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020852","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,9]]}}}